{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:14Z","timestamp":1792787834366,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"School-Level Scientific Research Affiliated Joint Project of Xiangnan University","id":[{"id":"https:\/\/ror.org\/05by9mg64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"2025 Hunan Provincial Natural Science Foundation Regional Joint Fund Project"},{"name":"Dongguan Science and Technology of Social Development Program","award":["20231800936452"],"award-info":[{"award-number":["20231800936452"]}]},{"name":"The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital) Dongguan People\u2019s Hospital","award":["Z202412"],"award-info":[{"award-number":["Z202412"]}],"id":[{"id":"https:\/\/ror.org\/022s5gm85","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021B1515140031"],"award-info":[{"award-number":["2021B1515140031"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16715-7","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:25:01Z","timestamp":1786400701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiangdi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"9","key":"16715_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20(9):624\u201339.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"16715_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"Cancer J Clin"},{"issue":"10454","key":"16715_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"M Meyer","year":"2024","unstructured":"Meyer M, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet (London England). 2024;404(10454):803\u201322.","journal-title":"Lancet (London England)"},{"issue":"6","key":"16715_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","volume":"40","author":"AC Tan","year":"2022","unstructured":"Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin oncology: official J Am Soc Clin Oncol. 2022;40(6):611\u201325.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"6","key":"16715_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/ijms20061431","volume":"20","author":"A Russo","year":"2019","unstructured":"Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci. 2019;20(6):1431.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"16715_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ijc.32097","volume":"145","author":"L Yi","year":"2019","unstructured":"Yi L, Fan J, Qian R, Luo P, Zhang J. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. INT J CANCER. 2019;145(1):284\u201394.","journal-title":"INT J CANCER"},{"issue":"21","key":"16715_CR7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC, Yanagitani N, Kim S, Sugawara S, Yu Y, Fan Y, Geater SL, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"key":"16715_CR8","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.phrs.2023.106668","volume":"188","author":"T Lei","year":"2023","unstructured":"Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C, Wang Z. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET\/MYC\/AXL axis. PHARMACOL RES. 2023;188:106668.","journal-title":"PHARMACOL RES"},{"issue":"11","key":"16715_CR9","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/annonc\/mdx404","volume":"28","author":"C Leduc","year":"2017","unstructured":"Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Annals oncology: official J Eur Soc Med Oncol. 2017;28(11):2715\u201324.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"2","key":"16715_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","volume":"142","author":"RP Graham","year":"2018","unstructured":"Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, Rimm DL. Worldwide Frequency of Commonly Detected EGFR Mutations. ARCH PATHOL LAB MED. 2018;142(2):163\u20137.","journal-title":"ARCH PATHOL LAB MED"},{"issue":"32","key":"16715_CR11","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1111\/1759-7714.15111","volume":"14","author":"H Chang","year":"2023","unstructured":"Chang H, Wang C, Tseng C, Huang K, Chen Y, Chang Y, Lai C, Fang W, Lin M, Chuang H. Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs. THORAC CANCER. 2023;14(32):3208\u201316.","journal-title":"THORAC CANCER"},{"issue":"1","key":"16715_CR12","first-page":"e1492","volume":"10","author":"U Batra","year":"2023","unstructured":"Batra U, Biswas B, Prabhash K, Krishna MV. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ OPEN RESPIR RES. 2023;10(1):e1492.","journal-title":"BMJ OPEN RESPIR RES"},{"issue":"9","key":"16715_CR13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3390\/cancers13092172","volume":"13","author":"A Passaro","year":"2021","unstructured":"Passaro A, Attili I, Rappa A, Vacirca D, Ranghiero A, Fumagalli C, Guarize J, Spaggiari L, de Marinis F, Barberis M, et al. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. CANCERS. 2021;13(9):2172.","journal-title":"CANCERS"},{"issue":"15","key":"16715_CR14","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.3390\/jcm13154476","volume":"13","author":"I Attili","year":"2024","unstructured":"Attili I, Asnaghi R, Vacirca D, Adorisio R, Rappa A, Ranghiero A, Lombardi M, Corvaja C, Fuorivia V, Carnevale Schianca A, et al. Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis. J CLIN MED. 2024;13(15):4476.","journal-title":"J CLIN MED"},{"issue":"4","key":"16715_CR15","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/jcm15041552","volume":"15","author":"K Kobayashi","year":"2026","unstructured":"Kobayashi K. TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. J CLIN MED. 2026;15(4):1552.","journal-title":"J CLIN MED"},{"issue":"s1","key":"16715_CR16","doi-asserted-by":"publisher","first-page":"S309","DOI":"10.3233\/TUB-230034","volume":"46","author":"J Moes-Sosnowska","year":"2024","unstructured":"Moes-Sosnowska J, Szpechcinski A, Chorostowska-Wynimko J. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Tumour biology: J Int Soc Oncodevelopmental Biology Med. 2024;46(s1):S309\u201325.","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biology Med"},{"issue":"1","key":"16715_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-021-00243-7","volume":"6","author":"F Zhang","year":"2022","unstructured":"Zhang F, Wang J, Xu Y, Cai S, Li T, Wang G, Li C, Zhao L, Hu Y. Co-occurring genomic alterations and immunotherapy efficacy in NSCLC. NPJ PRECIS ONCOL. 2022;6(1):4.","journal-title":"NPJ PRECIS ONCOL"},{"key":"16715_CR18","doi-asserted-by":"crossref","unstructured":"Yang L, Cheng J, Guo X, Xiao H, Kuang X, Yang Y, Zhang L, Zhang Q, Wang D, Xu Y et al. Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer. Respir Res. 2026:27(1):264","DOI":"10.1186\/s12931-026-03699-y"},{"key":"16715_CR19","doi-asserted-by":"publisher","first-page":"708294","DOI":"10.3389\/fonc.2021.708294","volume":"11","author":"J Dai","year":"2021","unstructured":"Dai J, Jiang M, He K, Wang H, Chen P, Guo H, Zhao W, Lu H, He Y, Zhou C. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. FRONT ONCOL. 2021;11:708294.","journal-title":"FRONT ONCOL"},{"issue":"3","key":"16715_CR20","first-page":"339","volume":"28","author":"W Deng","year":"2016","unstructured":"Deng W, Lei Y, Liu S, Yang J, Tu H, Yan H, Wu Y. Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19\/L858R. Chin J cancer Res = Chung-kuo yen cheng yen chiu. 2016;28(3):339\u201347.","journal-title":"Chin J cancer Res = Chung-kuo yen cheng yen chiu"},{"key":"16715_CR21","doi-asserted-by":"publisher","first-page":"107895","DOI":"10.1016\/j.lungcan.2024.107895","volume":"194","author":"M Wespiser","year":"2024","unstructured":"Wespiser M, Swalduz A, P\u00e9rol M. Treatment sequences in EGFR mutant advanced NSCLC. Lung cancer (Amsterdam Netherlands). 2024;194:107895.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"3","key":"16715_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cllc.2021.09.004","volume":"23","author":"JA Hellyer","year":"2022","unstructured":"Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakelee HA. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. CLIN LUNG CANCER. 2022;23(3):264\u201372.","journal-title":"CLIN LUNG CANCER"},{"key":"16715_CR23","doi-asserted-by":"publisher","first-page":"1661679","DOI":"10.3389\/fimmu.2025.1661679","volume":"16","author":"W Zhang","year":"2025","unstructured":"Zhang W, Tan L, Mu Q, Zhang H, Sun D. Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning. FRONT IMMUNOL. 2025;16:1661679.","journal-title":"FRONT IMMUNOL"},{"issue":"2","key":"16715_CR24","first-page":"177","volume":"38","author":"H Zhang","year":"2026","unstructured":"Zhang H, Zhou J, Liu J, Zhang P, Li X, Yu Y, Mao W, Sun D. Integrating AI-driven single-cell analysis to decode epithelial heterogeneity: A prognostic signature and translational immunotherapy strategy targeting KRT18-induced PD-L1 in lung adenocarcinoma. Chin J cancer Res = Chung-kuo yen cheng yen chiu. 2026;38(2):177\u201396.","journal-title":"Chin J cancer Res = Chung-kuo yen cheng yen chiu"},{"issue":"19","key":"16715_CR25","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.3390\/cancers13194926","volume":"13","author":"D Reita","year":"2021","unstructured":"Reita D, Pabst L, Pencreach E, Gu\u00e9rin E, Dano L, Rimelen V, Voegeli A, Vallat L, Mascaux C, Beau-Faller M. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. CANCERS. 2021;13(19):4926.","journal-title":"CANCERS"},{"issue":"4","key":"16715_CR26","first-page":"2677","volume":"14","author":"U Batra","year":"2022","unstructured":"Batra U, Nathany S, Sharma M, Mehta A, Dhanda S, Jose JT. Machine learning-based algorithm demonstrates differences in del19 and L858R EGFR subgroups in non-small cell lung cancer: a single center experience. AM J TRANSL RES. 2022;14(4):2677\u201384.","journal-title":"AM J TRANSL RES"},{"issue":"5","key":"16715_CR27","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/cancers14051143","volume":"14","author":"M Canale","year":"2022","unstructured":"Canale M, Andrikou K, Priano I, Cravero P, Pasini L, Urbini M, Delmonte A, Crin\u00f2 L, Bronte G, Ulivi P. The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. CANCERS. 2022;14(5):1143.","journal-title":"CANCERS"},{"key":"16715_CR28","doi-asserted-by":"publisher","first-page":"107249","DOI":"10.1016\/j.lungcan.2023.107249","volume":"181","author":"F Pezzuto","year":"2023","unstructured":"Pezzuto F, Hofman V, Bontoux C, Fortarezza F, Lunardi F, Calabrese F, Hofman P. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies? Lung cancer (Amsterdam Netherlands). 2023;181:107249.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"7","key":"16715_CR29","doi-asserted-by":"publisher","first-page":"e70058","DOI":"10.1111\/1759-7714.70058","volume":"16","author":"M Kim","year":"2025","unstructured":"Kim M, Park GS, Lee KY, Moon SW, Sung YE. Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker. THORAC CANCER. 2025;16(7):e70058.","journal-title":"THORAC CANCER"},{"key":"16715_CR30","doi-asserted-by":"publisher","first-page":"115622","DOI":"10.1016\/j.ejca.2025.115622","volume":"227","author":"FT Gallina","year":"2025","unstructured":"Gallina FT, Marinelli D, Taj\u00e8 R, Visca P, Cecere FL, Landi L, Buglioni S, Forcella D, Melis E, Najmeh S, et al. TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma. Eur J cancer (Oxford England: 1990). 2025;227:115622.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"1","key":"16715_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12890-025-03805-8","volume":"25","author":"J Li","year":"2025","unstructured":"Li J, Xu R, Wang D, Liang Z, Li Y, Wang Q, Bi L, Qi Y, Zhou Y, Li W. Non-invasive identification of TKI-resistant NSCLC: a multi-model AI approach for predicting EGFR\/TP53 co-mutations. BMC PULM MED. 2025;25(1):336.","journal-title":"BMC PULM MED"},{"issue":"6","key":"16715_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cllc.2025.04.007","volume":"26","author":"L Wei","year":"2025","unstructured":"Wei L, Lao Y, Fu T, Xie Z, Wang Y, Yang T, Huang L, Liu J, Shu M, Tian T, et al. Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. CLIN LUNG CANCER. 2025;26(6):478\u201391.","journal-title":"CLIN LUNG CANCER"},{"issue":"1","key":"16715_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.21037\/jtd-21-1921","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li S, Lyu Z, Cai J, Zheng N, Li Y, Xu T, Zeng H. The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. J THORAC DIS. 2022;14(1):185\u201393.","journal-title":"J THORAC DIS"},{"issue":"4","key":"16715_CR34","doi-asserted-by":"publisher","first-page":"104479","DOI":"10.1016\/j.esmoop.2025.104479","volume":"10","author":"S Hait","year":"2025","unstructured":"Hait S, Noronha V, Chowdhury A, Chaudhary A, Bawaskar B, Dahimbekar G, Ahmad S, Joshi A, Patil V, Menon N, et al. The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer. ESMO OPEN. 2025;10(4):104479.","journal-title":"ESMO OPEN"},{"issue":"1","key":"16715_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12967-025-06144-8","volume":"23","author":"B Zhang","year":"2025","unstructured":"Zhang B, Leung P, Cho WC, Wong C, Wang D. Targeting PI3K signaling in Lung Cancer: advances, challenges and therapeutic opportunities. J TRANSL MED. 2025;23(1):184.","journal-title":"J TRANSL MED"},{"key":"16715_CR36","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.phrs.2024.107123","volume":"202","author":"X Liu","year":"2024","unstructured":"Liu X, Mei W, Zhang P, Zeng C. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities. PHARMACOL RES. 2024;202:107123.","journal-title":"PHARMACOL RES"},{"issue":"10","key":"16715_CR37","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, et al. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. J Thorac oncology: official publication Int Association Study Lung Cancer. 2019;14(10):1784\u201393.","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"key":"16715_CR38","doi-asserted-by":"publisher","first-page":"22813774","DOI":"10.1177\/17588359251369038","volume":"17","author":"X Li","year":"2025","unstructured":"Li X, Ding K, Liu D, Wang Y, Xu Y. Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges. THER ADV MED ONCOL. 2025;17:22813774.","journal-title":"THER ADV MED ONCOL"},{"key":"16715_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2020.11.016","volume":"151","author":"S Arakawa","year":"2021","unstructured":"Arakawa S, Yoshida T, Shirasawa M, Takayanagi D, Yagishita S, Motoi N, Ohe Y. RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient. Lung cancer (Amsterdam Netherlands). 2021;151:101\u20133.","journal-title":"Lung cancer (Amsterdam Netherlands)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16715-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16715-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16715-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:08:45Z","timestamp":1790831325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16715-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16715"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16715-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9194785\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the Medical Ethics Committee of Dongguan People\u2019s Hospital (The Tenth Affiliated Hospital of Southern Medical University), Dongguan, China (approval No. LW2026-017). The present study involved only the secondary analysis of publicly available, de-identified cBioPortal data, and no identifiable participant information was accessed. Therefore, additional informed consent to participate was not required for the present study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1158"}}